Tildrakizumab Demonstrates Efficacy in Treating Patients with Psoriatic Arthritis

Tildrakizumab demonstrated superior efficacy and comparable safety versus placebo in patients with psoriatic arthritis (PsA), according to the results of a phase 2b study.
 
The study data were presented at the Annual European Congress of Rheumatology in Madrid, Spain.
 
Tildrakizumab, a humanized monoclonal antibody targeting interleukin (IL)-23p19, is currently approved for the treatment of moderate-to-severe plaque psoriasis. However, current guidelines recommend consideration of biological disease-modifying anti-rheumatic drugs (DMARDs) targeting IL-12/23 or IL-17 pathways in patients with PsA who have had an inadequate response to conventional therapies and for whom tumor necrosis factor inhibitors are not appropriate.
 
The 24-week study included 391 adults with PsA who had 3 or more tender and 3 or more swollen joints. Patients received either tildrakizumab 200 mg every 4 weeks, 200 mg, 100 mg, or 20 mg every 12 weeks or a placebo every 4 weeks. Stable concomitant methotrexate or leflunomide use was permitted but not mandated.
 
According to the data, by week 24, a significantly higher proportion of patients treated with tildrakizumab at any dose achieved a 90% reduction in Psoriasis Area and Severity Index (PASI 90) and a 50% reduction in American College of Rheumatology response criteria (ACR 50) versus placebo. Additionally, the study showed that response rates improved as the dose increased, although shortening the dosing interval of 200 mg from 12 to 4 weeks did not demonstrate a measurable increase in skin or joint response scores.
 
In patients who received 200 mg tildrakizumab every 12 weeks, 79.6% and 50% achieved PASI 75 and PASI 90, respectively, versus 16.7% and 7.1% in the placebo group.
 
The findings demonstrated a clear separation between tildrakizumab and the placebo as early as 8 weeks for ACR20 and 12 weeks for ACR50, according to the study.
 
Serious adverse events (AEs) were observed in 2.2% of patients treated with tildrakizumab and 2.5% of placebo-treated patients. The most commonly reported AEs included nasopharyngitis and diarrhea, with no reports of candidiasis, inflammatory bowel disease, major adverse cardiac events, or malignancy.
 
Reference
 
Mease PJ, Chohan S, Garcia FJ, et al. Randomized, double-blind, placebo-controlled, multiple-dose, phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti-interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. EULAR 2019; Madrid, Spain. Abstract LB00002.
 



Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Related Articles

Upadacitinib (Rinvoq, AbbVie) is indicated for adults with moderate-to-severe rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Top news of the day from across the health care landscape.
Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$